Delivery Order SPE2DB22D3019-SPE2DB25FK3QB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) valued at $1,605.86. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a routine pharmaceutical supply transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $1,250.64. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $28,970.38. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and represents a component of the company's broader pharmaceutical supply relationship with the federal government. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package. This order is valued at $1,825.56 with a firm fixed price structure and carries a completion date of July 30, 2025. The contract involves no set-aside designation, indicating it was competitively awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract value of $37,834.09. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an open procurement process. The contract is scheduled for ultimate completion on September 11, 2025, with performance taking place at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $5,506.32 and an ultimate completion date of August 4, 2025. The contract carries no set-aside designation and was awarded competitively. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $11,089.97. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) with a ceiling value of $17,772.34. This competitive award, which carries a firm fixed price and completion date of December 3, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $6,100.21 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The order was placed to the company's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $4,438.25 and a firm fixed price structure. This delivery order was competitively awarded with no set-aside designation and is scheduled for completion by November 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK3QBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) with a ceiling value of $4,453.44. This competitively awarded, firm fixed-price delivery order is scheduled for completion by May 9, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete successfully in the federal pharmaceutical procurement market. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a prime pharmaceutical vendor for the Defense Health Agency and other federal healthcare systems, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies supporting military healthcare operations globally. The current delivery order for this diabetes medication reflects the company's role in providing critical pharmaceutical commodities to support federal medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 5/8/25 |